Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response

被引：12
作者：
Goode, Emily F. [1 ,2 ]
Torres, Evanthia T. Roussos [3 ]
Irshad, Sheeba [4 ,5 ]
机构：
[1] Inst Canc Res, London, England
[2] Canc Res UK CRUK Clin Fellow, London, England
[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90007 USA
[4] Kings Coll London, Sch Canc & Pharmaceut Sci, London, England
[5] Canc Res UK CRUK Clinician Scientist, London, England
来源：
FRONTIERS IN MOLECULAR BIOSCIENCES | 2021年 / 8卷
关键词：
lymph node; immune checkpoint inhibitor (ICI); biomarker; immune microenviroment; immune profiling; immune surveillance; CD8(+) T-CELLS; PD-1; BLOCKADE; SUPPRESSOR-CELLS; B-CELLS; TUMOR; IMMUNOTHERAPY; NIVOLUMAB; PEMBROLIZUMAB; INDUCTION; MONOTHERAPY;
D O I：
10.3389/fmolb.2021.674558
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The need for predictive biomarkers that can accurately predict patients who will respond to immune checkpoint inhibitor (ICI) immunotherapies remains a clinically unmet need. The majority of research efforts have focused on expression of immune-related markers on the tumour and its associated tumour microenvironment (TME). However, immune response to tumour neoantigens starts at the regional lymph nodes, where antigen presentation takes place and is regulated by multiple cell types and mechanisms. Knowledge of the immunological responses in bystander lymphoid organs following ICI therapies and their association with changes in the TME, could prove to be a valuable component in understanding the treatment response to these agents. Here, we review the emerging data on assessment of immunological responses within regional lymph nodes as predictive biomarkers for immunotherapies.
引用
收藏
页数：9
相关论文
共 54 条
  • [1] Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node
    Alonso, Ruby
    Flament, Heloise
    Lemoine, Sebastien
    Sedlik, Christine
    Bottasso, Emanuel
    Peguillet, Isabel
    Premel, Virginie
    Denizeau, Jordan
    Salou, Marion
    Darbois, Aurelie
    Nunez, Nicolas Gonzalo
    Salomon, Benoit
    Gross, David
    Piaggio, Eliane
    Lantz, Olivier
    [J]. NATURE COMMUNICATIONS, 2018, 9
  • [2] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [3] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
  • [4] Tertiary lymphoid structures improve immunotherapy and survival in melanoma
    Cabrita, Rita
    Lauss, Martin
    Sanna, Adriana
    Donia, Marco
    Larsen, Mathilde Skaarup
    Mitra, Shamik
    Johansson, Iva
    Phung, Bengt
    Harbst, Katja
    Vallon-Christersson, Johan
    van Schoiack, Alison
    Loevgren, Kristina
    Warren, Sarah
    Jirstroem, Karin
    Olsson, Hakan
    Pietras, Kristian
    Ingvar, Christian
    Isaksson, Karolin
    Schadendorf, Dirk
    Schmidt, Henrik
    Bastholt, Lars
    Carneiro, Ana
    Wargo, Jennifer A.
    Svane, Inge Marie
    Jonsson, Goran
    [J]. NATURE, 2020, 577 (7791) : 561 - +
  • [5] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
    Carbone, D. P.
    Reck, M.
    Paz-Ares, L.
    Creelan, B.
    Horn, L.
    Steins, M.
    Felip, E.
    van den Heuvel, M. M.
    Ciuleanu, T. -E.
    Badin, F.
    Ready, N.
    Hiltermann, T. J. N.
    Nair, S.
    Juergens, R.
    Peters, S.
    Minenza, E.
    Wrangle, J. M.
    Rodriguez-Abreu, D.
    Borghaei, H.
    Blumenschein, G. R.
    Villaruz, L. C.
    Havel, L.
    Krejci, J.
    Corral Jaime, J.
    Chang, H.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Chen, A. C.
    Socinski, M. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) : 2415 - 2426
  • [6] An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy
    Chamoto, K
    Wakita, D
    Narita, Y
    Zhang, Y
    Noguchi, D
    Ohnishi, H
    Iguchi, T
    Sakai, T
    Ikeda, H
    Nishimura, T
    [J]. CANCER RESEARCH, 2006, 66 (03) : 1809 - 1817
  • [7] Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
    Chamoto, Kenji
    Chowdhury, Partha S.
    Kumar, Alok
    Sonomura, Kazuhiro
    Matsuda, Fumihiko
    Fagarasan, Sidonia
    Honjo, Tasuku
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (05) : E761 - E770
  • [8] Oncology Meets Immunology: The Cancer-Immunity Cycle
    Chen, Daniel S.
    Mellman, Ira
    [J]. IMMUNITY, 2013, 39 (01) : 1 - 10
  • [9] The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
    Dammeijer, Floris
    van Gulijk, Mandy
    Mulder, Evalyn E.
    Lukkes, Melanie
    Klaase, Larissa
    van den Bosch, Thierry
    van Nimwegen, Menno
    Lau, Sai Ping
    Latupeirissa, Kitty
    Schetters, Sjoerd
    van Kooyk, Yvette
    Boon, Louis
    Moyaart, Antien
    Mueller, Yvonne M.
    Katsikis, Peter D.
    Eggermont, Alexander M.
    Vroman, Heleen
    Stadhouders, Ralph
    Hendriks, Rudi W.
    von der Thusen, Jan
    Grunhagen, Dirk J.
    Verhoef, Cornelis
    van Hall, Thorbald
    Aerts, Joachim G.
    [J]. CANCER CELL, 2020, 38 (05) : 685 - +
  • [10] Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
    DeFalco, Jeff
    Harbell, Michael
    Manning-Bog, Amy
    Baia, Gilson
    Scholz, Alexander
    Millare, Beatriz
    Sumi, May
    Zhang, Danhui
    Chu, Felix
    Dowd, Christine
    Zuno-Mitchell, Patricia
    Kim, Dongkyoon
    Leung, Yvonne
    Jiang, Shuwei
    Tang, Xiaobin
    Williamson, Kevin S.
    Chen, Xiaomu
    Carroll, Sean M.
    Santo, Gregg Espiritu
    Haaser, Nicole
    Ngan Nguyen
    Giladi, Eldar
    Minor, David
    Tan, Yann Chong
    Sokolove, Jeremy B.
    Steinman, Lawrence
    Serafini, Tito A.
    Cavet, Guy
    Greenberg, Norman M.
    Glanville, Jacob
    Volkmuth, Wayne
    Emerling, Daniel E.
    Robinson, William H.
    [J]. CLINICAL IMMUNOLOGY, 2018, 187 : 37 - 45
123456